The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

REFERENCES

• Rahman A, Treat J, Roh JK, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxor-ubicin. J Clin Oncol 1990;8:1093–1100.
   PubMed Web of Science ®Google Scholar
• Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992;52:3255–3261.
   Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992;52:891–896.
   PubMed Web of Science ®Google Scholar
• Forssen EA, Male-Brune R, Adler-Moore JP et al. Fluores-cence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res 1996;56:2066–2075.
   PubMed Web of Science ®Google Scholar
• Pouna P, Bonoron-Adele S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996;117:1593–1599.
   PubMed Web of Science ®Google Scholar
• Wang Y, Eksborg S, Lewensohn R, Lindberg A, Liliemark E. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxor-ubicin in resistant K562 cells. Anticancer Drugs 1999;10: 921–928.
   Google Scholar
• Safra T, Muggia F, Jeffers S et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029–1033.
   PubMed Web of Science ®Google Scholar
• Safra T. Cardiac safety of liposomal anthracyclines. Oncolo-gist 2003;8(Suppl. 2):17–24.
   Google Scholar
• Gill PS, Espina BM, Muggia F et al. Phase I/II clinical and pharmacoldnetic evaluation of liposomal daunorubicin. J Chin Oncol 1995;13:996–1003.
   PubMed Web of Science ®Google Scholar
• Pea F, Russo D, Michieli M et al. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Cancer Chemother Pharmacol 2000;46:279–286.
   PubMed Web of Science ®Google Scholar
• Rahman A, White G, More N, Schein PS. Pharmacological, toxicological, and therapeutic evaluation in mice of doxor-ubicin entrapped in cardiolipin liposomes. Cancer Res 1985;45:796–903.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Lokhorst HM, Roovers DJ, van Heugten HG. Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for lipo-some-encapsulated daunorubicin. Leuk Res 1998;22:249–256.
   Google Scholar
• Sargent JM, Elgie AW, Williamson CJ, Lewandowitz GM, Taylor CG. In vitro sensitivity to the liposomal preparation, DaunoXome in CLL. Anticancer Res 1999;19:3253–3257.
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R et al.; TLC D-99 Study Group. Liposome encapsulated doxorubicin compared with conven-tional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25–36.
   Google Scholar
• Batist G, Ramakrishnan G, Rao CS et al. Reduced cardio-toxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Chin Oncol 2001;19:1444–1454.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Wigler N, Inbar M et al.; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1 (CAELYX/D0)d1) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–449.
   Google Scholar
• Forssen EA, Ross ME. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 1994;4:481–512.
   Google Scholar
• Hempel G, Reinhardt D, Creutzig U, Boos J. Population pharmacokinetics of liposomal daunorubicin in children. Br J Pharmacol 2003;56:370–377.
   Web of Science ®Google Scholar
• Belott R, Auvrignon A, Leblanc T et al. Pharmacoldnetics of liposomal daunorubicin (DaunoXome) during a phase I/II study in children with relapsed acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001;47:15–21.
   PubMed Web of Science ®Google Scholar
• Pea F, Russo D, Michieli M et al. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukemia. Chin Pharmacokinet 2003;42:851–862.
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Ermacora A et al. Liposome encapsulated daunorubicin for PGP-related multidrug resis-tance. Br J Haematol 1999;106:92–99.
   PubMed Web of Science ®Google Scholar
• Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Chin Cancer Res 2000;6:1949–1957.
   Web of Science ®Google Scholar
• Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Antic-ancer Res 2002;22:2131–2135.
   Google Scholar
• Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711–716.
   PubMed Web of Science ®Google Scholar
• Liu FT, Kelsey SM, Newland AC, Jia L. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukemic cells. Br J Haematol 2002;117:333–342.
   PubMed Web of Science ®Google Scholar
• Shacter E, Williams JA, Hinson R1\4, Senturker S, Lee YJ. Oxidative stress interferes with cancer chemotherapy: inhibi-tion of lymphoma cell apoptosis and phagocytosis. Blood 2000;96: 307–313.
   Google Scholar
• Gill PS, Wernz J, Scadden DT et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomy-cin, and vincristine in AIDS-related Kaposi's sarcoma. J Chin Oncol 1996;14:2353–2364.
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Thomas AL, Sharma RA et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002;87:15–20.
   Google Scholar
• Cortes JE, Fassas A, Anagnostopoulos A et al. Liposomal daunorubicin (DaunoXome) has minimal cardiotoxicity in patients with prior anthracycline therapy for acute myeloid leukemia. Blood 1999;94:508a.
   Google Scholar
• Todeschini G, Tecchio C, Meneghini V et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunor-ubicin. Leukemia 1998;12:144–149.
   PubMed Web of Science ®Google Scholar
• Head D, Kopecky KJ, Weick J et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995;86:1717–1728.
   PubMed Web of Science ®Google Scholar
• Rees JK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party. Br J Haematol 1996;94: 89–98.
   Google Scholar
• Usui N, Dobashi N, Kobayashi T et al. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. J Chin Oncol 1998;16:2086–2092.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999;17:81–87.
   PubMed Web of Science ®Google Scholar
• Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D. Liposome encapsulated daunorubicin (daunoxome) for acute leukemia. Haematologica 2000;85:324–425.
   Google Scholar
• Bieker R, Lerchenmäller C, Wehmeyer J et al. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep 2003;10:915–920.
   PubMed Web of Science ®Google Scholar
• Fassas A, Buffels R, Anagnostopoulos A et al. Safety and early efficacy assessment of liposomal daunorubicin (daunoxome) in adults with refractory or relapsed acute myeloblastic leukemia: a phase 1-11 study. Br J Haematol 2002;11 6:308–315.
   Google Scholar
• Fassas A, Buffels R, Kaloyannidis P, Anagnostopoulos A. Safety of high dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia. Br J Haematol 2003;122:161–162.
   PubMed Web of Science ®Google Scholar
• Cortes J, Estey E, O'Brien S et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001;92:7–14.
   Google Scholar
• Russo D, Piccaluga PP, Michieli M et al. Liposomal daunorubicin (daunoxome) for treatment of poor-risk acute leukemia. Ann Hematol 2002;81:462–466.
   PubMed Web of Science ®Google Scholar
• Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U. Effektive Redizivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin. Klin Pädiatr 2002;214:188–194.
   PubMed Web of Science ®Google Scholar
• Clavio M, Venturino C, Pierri I et al. Combination of liposomal daunorubicin (daunoxome), fludarabine, and cytar-abine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004;83:696–703.
   PubMed Web of Science ®Google Scholar
• Tökes ZA, St. Peteri AK, Todd JA. Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier. Brain Res 1980;188:282–286.
   Google Scholar
• Lippens RJ. Liposomal daunorubicin (daunoxome) in chil-dren with recurrent or progressive brain tumors. Pediatr Hematol Oncol 1999;16:131–139.
   PubMed Web of Science ®Google Scholar
• Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubici-nol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999;44:173–176.
   Google Scholar
• Piccaluga PP, Visani G, Martinelli G et al. Liposomal daunorubicin (daunoxome) for treatment of relapsed menin-geal acute myeloid leukemia. Leukemia 2002;16:1880–1881.
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H, Albitar M et al. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelo-genous leukemia or myelodysplastic syndrome. Cancer 2001;97:1234–1241.
   Web of Science ®Google Scholar
• Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles F. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887–891.
   PubMed Web of Science ®Google Scholar